Premium
Biochemical markers of bone turnover in women with surgically treated carcinoma of the breast
Author(s) -
LI F.,
PITT P. I.,
SHERWOOD R.,
BARRETTT J.,
HOUGHTON J.,
PARSONS V.,
MONIZ C.
Publication year - 1993
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.1993.tb00967.x
Subject(s) - deoxypyridinoline , bone remodeling , pyridinoline , tamoxifen , medicine , endocrinology , bone resorption , breast cancer , hydroxyproline , carcinoma , alkaline phosphatase , cancer , urology , osteocalcin , chemistry , enzyme , biochemistry
. Biochemical markers of bone turnover were measured in fasting urine and blood samples obtained from 38 postmenopausal women with previous surgi cal treatment of breast cancer combined with adjuvant chemotherapy, tamoxifen, or placebo. Significantly elevated urinary pyridinoline as nmol mmol ‐1 creatinine (47.5 and 42.5 in tamoxifen and placebo treated patients compared with 26.3 in normal controls, both P <0.001) and deoxypyridinoline (11.9 and 10.5 com pared with 6.3, P <0.001 and P =0.002 respectively) were found with unchanged urinary hydroxyproline, serum alkaline phosphatase and procollagen I carboxyterminal peptide (PICP). These findings suggest enhanced bone resorption resulting from the humoral osteoclast activating effect of the previous breast cancer or underlying carcinoma recurrence. Alternatively the raised pyridinium excretion might indicate an altered cross linking composition of bone collagen. No specific effect on bone metabolism was found with tamoxifen treatment as all measured parameters were similar in both tamoxifen ex‐users and non‐users. This confirmed the safety of tamoxifen therapy with respect to bone.